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  Interferon (IFN) has therapeutic potential for a wide range 
of  infectious  and  proliferative  disorders.  However,  the 
half-life of IFN is too short to have a stable therapeutic effect. 
To overcome this problem, serum immunoglobulin has been 
fused to IFN. In this study, the efficacy of serum immuno-
globulin fused INFs (si-IFN1 and si-IFN2) was evaluated on 
athymic mice bearing colon 26 adenocarcinoma cells. Seven 
days after the implantation of tumor cells, each group of 
mice was injected once a week with si-IFN1 and si-IFN2 at 
two different concentrations (10 × : 30 µg/kg and 50 × : 150 
µg/kg). A slight anti-tumoral effect was observed in all 10 × 
groups compared to the control. In the 50 × groups, however, 
si-IFN1 and si-IFN2 showed significant anti- tumoral effects 
compared to the control. To gain more information on the 
mechanisms associated with the decrease of tumor size, a 
Western  blot  assay  of  apoptosis-related  molecules  was 
performed. The protein expression of cytochrome c, caspase 
9, 6, and 3 were increased by si-IFN1 and si-IFN2. These 2 
IFNs also increased the expressions of p53, p21, Bax and 
Bad.  Interestingly,  si-IFN1  and  si-IFN2  decreased  the 
expression  of  VEGF-β.  Taken  together,  serum  immuno-
globulin fused IFNs increased therapeutic efficacy under 
current experimental condition.
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Introduction 
  Interferon (IFN) is a cytokine produced and secreted by 
eukaryotic cells in response to stimulation by viruses, 
bacteria, and mitogens and mediates diverse biological 
activities by binding to a specific receptor on the cell 
surface [1,10]. IFNs have therapeutic potential for a wide 
range of infectious and proliferative disorders due to their 
pleitropic effects on multiple metabolic, immunologic and 
pathologic events [3,6,9]. However, the half-life of IFN is 
too short for a stable therapeutic effect. To overcome this 
problem, several methods are used for improving the 
stability of proteins. One of the methods is chemical 
modification of a polypeptide with highly soluble macro-
molecules such as polyethylene glycol (PEG) which 
prevents the polypeptides from making contact with 
proteases. However, such pegylated polypeptides have the 
disadvantage of lowering both the activity and production 
yield of an active substance as the molecular weight of 
PEG increases. Another approach for enhancing the in vivo 
stability of the IFN is to conjugate the IFN with a stable 
serum immunoglobulin. As an improved method for enhancing 
the stability of an active polypeptide and simultaneously 
maintaining the in vivo activity thereof, the two IFN 
conjugate si-IFN1 and si-IFN2 comprising an IFN, PEG 
and serum immunoglobulin, were interlinked to one another.
    The present paper reports that IFN-α  modified with 
serum immunoglobulin (si-IFN1 and si-IFN2) inhibits 
tumor growth in athymic mice bearing colon 26 adenocar-
cinoma cells.
Materials and Methods
Reagents and cell culture
  Recombinant IFN-α, serum immunoglobulin fused IFN-
α (si-IFN1 and si-IFN2), and peginterferon α-2a were 
supplied by Hanmi Pharmaceutical (Korea). The efficacy 
of several IFNs was compared to efficacy-proven inter-
feron, peginterferon α-2a, which is a covalent conjugate of 
recombinant  α-2a interferon with a single branched 
bis-monomethoxy PEG chain (Roche, USA). The si-IFN1, 46    Jun-Sung Kim et al.
si-IFN2, and PEGASYS were administered at  two different 
concentrations (10 × groups: 30 µg/kg and 50 × groups: 
150 µg/kg). The mouse colon 26 adenocarcinoma cells 
(CT-26) were purchased from the Korean Cell Line Bank 
(KCLB, Korea). Colon 26 adenocarcinoma cells were 
cultured with RPMI 1640 medium (Gibco, USA) supple-
mented with 10% fetal bovine serum (FBS; Gibco, USA) 
in an atmosphere of 5% CO2 in an incubator at 37
oC. 
Experimental animals
  Specific pathogen-free male athymic BALB/c nude mice 
were purchased from the SLC (Shizuoka Institute for 
Laboratory Animals Center, Japan). Athymic nude mice 
were maintained at 23 ± 2
oC , with a relative humidity of 50 
± 20% and a 12 h light/dark cycle. After 7 days of tumor 
cell inoculation, the mice were grouped as follows: control, 
10 × and 50 × IFN concentrations. All the procedures for 
handling and caring for the animals were followed by the 
guidelines given in the NIH Guide for the Care and Use of 
Laboratory Animals (NIH Publication No. 85-23, 1985, 
revised 1996, USA). All of the experiments were conducted 
to minimize the number of animals used and the suffering 
caused by the procedures used in the present study.
Tumor cell inoculation and treatment procedure
  Mice were inoculated subcutaneously with 5 × 10
5 colon 
26 adenocarcinoma cells in RPMI 1640 with 10% FBS. 
Seven days after tumor cell inoculation, each mouse was 
treated with recombinant IFN-α, si-IFN1, si-IFN2 and 
peginterferon α-2a by intratumoral injection. IFN-α was 
injected every day for 21 days, the others were injected on 
days 7, 14 and 21 [5].
Serum and hematological analysis
  Blood samples for hematology were obtained from 5 mice 
in each group every week. Every week clinical biochemistry 
determinations were also made on the serum harvested from 
blood samples obtained from the mice. The following 
parameters were assayed: total protein (TPROT), albumin 
(ALB), total bilirubin (TBILI), aspartate aminotransferase 
(AST), alanine aminotransferase (ALT), glucose (GLU), 
blood urea nitrogen (BUN), creatinine (CREAT).
Measurement of tumor volume
  Tumor volume was measured on days 7, 14 and 21 with 
the aid of vernier calipers. At necropsy, the tumor volume 
was estimated for the largest (a) and the smallest (b) 
diameter, and the tumor volume was calculated as V = 
ab
2/2.
Western blot
  Protein was extracted from tumor tissues in recombinant 
IFN-α, si-IFN1, si-IFN2, and peginterferon α-2a in 50 × . 
The extracts were added to the sample buffer. Samples 
were boiled for 10 min, and proteins were separated on 
15% SDS-PAGE for 18 h. The nitrocellulose membrane 
was rinsed twice in Tween 20-TBS (T-TBS) with 5% skim 
milk. Subsequently, the membranes were incubated with  a 
1：2,500 dilution of primary antibody (cytochrom c, 
caspase 3, 6, and 9, and p53, p21, Bax, Bad, VEGF-β, and 
FGF-2) in T-TBS buffer for 3 h. They were then washed 
twice for 10 min in T-TBS buffer, incubated with a 1：
5,000 dilution of secondary antibody conjugated to HRP 
(Santa Cruz, USA) in T-TBS buffer for 1 h. After washing, 
the bands-of-interest were pictured by luminescent image 
analyzer LAS-3000 (Fujifilm, Japan).
Statistical analysis
  The results were expressed as mean ± SD values for 
independent experiments. Statistical analysis was performed 
on all groups using the t test.
Results
Clinical hematology and biochemistry
  In the hematological test of the 10 × group, there was no 
significant change after 1, 2 and 3 weeks (data not shown), 
however, in the 50 × group, the WBC value was increased 
in si-IFN2, peginterferon α-2a and IFN- α compared to the 
control after 2 weeks. This pattern was also observed in the 
lymphocyte value (Fig. 1A). After 3 weeks, the  increase of 
WBC’s and lymphocytes was observed in the si-IFN2, 
peginterferon α-2a and IFN-α groups compared to the 
control (Fig. 1B). Interestingly, the significant change in 
the monocyte level observed at 2 weeks was not main-
tained until 3 weeks (Fig. 1). In the biochemical test of 10 
× group, a decrease of BUN was observed at 2 weeks in 
si-IFN2, peginterferon α-2a and IFN-α group compared to 
the control and this decrease was maintained at 3 weeks 
(Fig. 2). In the biochemical test of the 50 × group, a 
decrease of BUN was observed only at 3 weeks in the 
si-IFN2, peginterferon α-2a and IFN-α group comparing to 
the control (Fig. 3). In particular, the level of ALT was 
decreased in peginterferon α- 2a and IFN-α group com-
paring to the control at 3 weeks (Fig. 3).
Tumor  growth  was  inhibited  by  si-IFN1  and 
si-IFN2 treatment
  In the 10 × group, the tumor volume decreased slightly in 
the si-IFN1, si-IFN2, peginterferon α-2a and IFN-α group 
compared to control (data not shown). In the 50 × group, 
however, the tumor volume decreased significantly in mice 
treated with si-IFN1, si-IFN2, peginterferon α-2a and IFN- 
α compared to the control (Fig. 4).
Level of pro-apoptotic molecules was increased in 
tumor tissue by modified IFNs
  The expression levels of cytochrome c, caspase 6, and Tumor-inhibitory effects of modified IFN-α    47
Fig. 2. Concentrations of blood urea nitrogen (BUN) in the 10 ×
interferon group. Clinical biochemistry determinations were 
made on serum harvested from the blood of mice. BUN was 
measured at 1 week (data not shown), 2 weeks and 3 weeks after 
tumor cells inoculation (n = 5). 10 × interferon group: 
concentration of si-IFN1 and si-IFN2 (30 µg/kg), Each point 
represents the mean ± SD. *Significantly different from control 
(p < 0.05). **Significantly different from control (p < 0.01).
Fig. 1. Hematological assay of differential leukocytes in the 50 × interferon group. Blood samples for hematological determinations were
obtained from 5 mice. The differential leukocyte count was measured at 1 week (data not shown), 2 weeks (A) and 3 weeks (B) after 
tumor cells inoculation (n = 5). 50 × interferon group: concentration of si-IFN1 and si-IFN2 (150 µg/kg), WBC: white blood cell, LY: 
lymphocyte, MO: monocyte.  Each point represents the mean ± SD. *Significantly different from control (p < 0.05). **Significantly 
different from control (p < 0.01).
Fig. 3. Concentrations of blood urea nitrogen (BUN) and alanine 
aminotransferase (ALT) in the 50 × interferon group. BUN and ALT
were measured after tumor cells inoculation (n = 5). 50 × interferon 
group: concentration of si-IFN1 and si-IFN2 (150 µg/kg), Each point
represents the mean ± SD. *Significantly different from control (p <
0.05). **Significantly different from control (p < 0.01).
caspase 3 were increased in the si-IFN1, si-IFN2, pegin-
terferon  α-2a and IFN-α  treated groups of 50 × 
concentration compared to the control. The expression of 
caspase 9 was observed clearly in si-IFN1 and si-IFN2 
only. The expression level of p53 was slightly increased, 
however, a distinct increase of p21 was observed in 
si-IFN1 only. The expression of BAD was significantly 
increased in si-IFN1 and si-IFN2; however, no change of 
Bax was observed (Fig. 5).
A decrease of proangiogenic molecule was observed 
in tumor tissue treated with modified IFNs
  In the Western blot of pro-angiogenic molecule, the 
expression level of VEGF-β was decreased in the si-IFN1, 
si-IFN2, peginterferon α-2a and IFN-α treated groups. The 
decrease of the expression level was observed particularly 
in si-IFN1, si-IFN2, and peginterferon α-2a compared to 
the control (Fig. 6).
Discussion
  IFN-α, the first cytokine to be produced by recombinant 48    Jun-Sung Kim et al.
Fig. 4. Effects of interferons on tumor growth inhibition. Mice were inoculated with 5 × 10
5 colon 26 adenocarcinoma cells in RPMI 
1640 with 10% FBS subcutaneously. Seven days after tumor cell inoculation, the tumor size was measured. The mice were then treated
with different interferons by intratumoral injection. IFN-α was injected every day for 3 weeks, the others were injected at 1 week, 2 
weeks and 3 weeks. Tumor volume was estimated for the largest (a) and smallest (b) diameter, and the tumor volume was calculated using
V= ab
2/2. Each point represents the mean ± SD. *Significantly different from control (p < 0.05). **Significantly different from control
(p < 0.01).
Fig. 5. Change of pro-apoptotic molecules in tumor tissue treated with 50 × groups. Protein samples were extracted from the tumor 
tissues of control, si-IFN1, si-IFN2, peginterferon α-2a and IFN-α treated groups at 50 × concentrations. Protein sample were prepared
for Western blot using antibodies to mouse cytochrome c, caspase 9, caspase 6, and caspase 3, p53, p21, Bax and Bad. Each band was
further analyzed by densitometer. Each number on the figure represents the density compared control.
DNA technology, has been identified as a pivotal regulator 
of cellp growth, differentiation, cell to cell communication 
and signal pathway [4]. Although there are many advan-
tages in the use of IFN-α in various diseases, clinical trials Tumor-inhibitory effects of modified IFN-α    49
Fig. 6. Change of angiogenesis-related molecules in tumor tissue
of mice. Protein samples were extracted from the tumor tissues of
control, si-IFN1, si-IFN2, peginterferon α-2a and IFN-α treated 
groups in 50 ×. Protein samples were prepared for Western blot 
using antibodies to mouse VEGF-β and FGF-2. Each band was 
further analyzed by densitometer program. Each number on the 
figure represents the density compared to the control.
have been limited due to their disadvantages such as their 
short half-life in in vivo systems. To overcome this dis-
advantage, various trials have been carried out using them 
in combination with other agents and making modifications 
to recombinant IFN-α. The present paper reports that a 
once-a-week injection of serum immunoglobulin fused 
IFN-α into athymic nude mice bearing tumor cells can 
inhibit tumor growth effectively. IFN-α is a multifunctional 
regulatory cytokine regulating cell function and proliferation. 
In the present experiments, serum immunoglobulin fused 
IFN-α named si-IFN1 and si-IFN2 was used. The results 
showed that at 21 days after tumor cells inoculation, the 
mean tumor volumes of si-IFN1, si-IFN2, peginterferon α
-2a and IFN-α treated with 50 × were significantly decreased 
compared to the control. In the biochemical tests of the 50 
× group, a decrease of BUN was observed in the si-IFN2, 
peginterferon α-2a and IFN- α group comparing to the 
damage but also dehydration. ALT is a predominantly 
hepatocyte enzyme and increase of ALT activity is known 
to be highly associated with liver damage. However, the 
current study is an initial report on the screening tests for 
the potential effects of various IFN types as antitumor 
drugs. These tests are based on various blood or serum 
measurements: (a) total white blood cell counts; (b) BUN 
for kidney toxicity and (c) ALT for liver toxicity. On the 
basis of the limited parameters tested, although varying in 
sensitivity, our data seem to correlate with the reduced 
toxicity and antitumor effects of the IFNs tested.  However, 
the final validation of these tests, especially the BUN and 
ALT, will require both further study of the histopathologic 
effects and correlation with the results from further 
efficacy trials over an extended period. Further studies of 
this type are essential.
    The pivotal events of tumor growth inhibition are 
apoptosis and anti-angiogenesis. Apoptosis is orchestrated 
by various molecules including extrinsic and intrinsic 
pathways. Also, a recent study reported that the IFN- 
family increased apoptosis in vitro [2]. To confirm the 
effect of serum immunoglobulin fused IFN-α  to the 
pro-apoptotic function, we performed a Western Blot test. 
In the extrinsic pathway related to the death receptor, an 
increase of cytochrome c, caspase 3, 6, and 9 was observed 
in si-IFN1 and si-IFN2. Cytochrome c is located in the 
mitochondria of all aerobic cells and is involved in the 
electron transport system that functions in oxidative 
phosphorylation. In addition to its role in oxidative phosphory-
lation, the release of cytochrome c from the mitochondrial 
intermembrane space results in nuclear apoptosis. Binding 
of Apaf-1 to cytochrome c allows Apaf-1 to form a ternary 
complex with, and activate, the initiator procaspase-9 [8]. 
In the intrinsic pathway associated with mitochondria, an 
increase of p53, p21 and Bad was also detected. Takaoka et 
al. [7] demonstrated that transcription of the p53 gene was 
induced by IFN-α, accompanied by an increase in p53 
protein levels and they provided examples in which p53 
gene induction by IFN-α  indeed contributed to tumor 
suppression. Our study also confirmed that si-IFN1 and 
si-IFN2 showed strong anti-tumor activity similar to that of 
peginterferon α-2a.
  The expansion of the tumor masses depends on neovascu-
larization and the formation of new vasculature involves 
multiple, interdependent steps [3]. In addition, the onset of 
angiogenesis involves a change in the local equilibrium 
between pro-angiogenic and anti-angiogenic molecules 
[3,9]. The key molecules associated with pro-angiogenesis 
include fibroblast growth factor 2 (FGF2) and vascular 
endothelial cell growth factor beta (VEGF-β). FGF2 is a 
wide-spectrum mitogenic, angiogenic, and neurotrophic 
factor that is expressed at low levels in many tissues and 
cell types and reaches high concentrations in the brain and 
pituitary. FGF2 has been implicated in a multitude of 
physiologic and pathologic processes, including limb 
development, angiogenesis, wound healing, and tumor 
growth. In our study, to evaluate the efficiency of serum 
immunoglobulin fused IFN-α  to anti-angiogenesis, the 
expression level of VEGF-β and FGF2 was measured by 
Western Blot. Our results showed that the expression level 
of VEGF-β was decreased in the si-IFN1, si-IFN2, pegin-
terferon α-2a and IFN-α treated groups. The decrease of 
the expression level was observed prominently in the 
si-IFN2 and peginterferon α-2a treated groups compared 
to the control. These data suggest that inhibition of tumor 
growth may be also due to the anti-angiogenic effect of 
si-IFN1 and si-IFN2.
    In conclusion, serum immunoglobulin fused IFN-α, 
si-IFN1 and si-IFN2 are able to inhibit the tumor growth of 
athymic mice bearing colon 26 adenocarcinoma cells and 50    Jun-Sung Kim et al.
the inhibitory effects may be associated with facilitating 
apoptosis and suppressing angiogenesis.
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